[go: up one dir, main page]

WO2012087004A3 - Use of upr signaling pathway genes ire1 and hxl1 for treatment of fungal infection and meningitis - Google Patents

Use of upr signaling pathway genes ire1 and hxl1 for treatment of fungal infection and meningitis Download PDF

Info

Publication number
WO2012087004A3
WO2012087004A3 PCT/KR2011/009862 KR2011009862W WO2012087004A3 WO 2012087004 A3 WO2012087004 A3 WO 2012087004A3 KR 2011009862 W KR2011009862 W KR 2011009862W WO 2012087004 A3 WO2012087004 A3 WO 2012087004A3
Authority
WO
WIPO (PCT)
Prior art keywords
meningitis
hxl1
ire1
treatment
effect
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2011/009862
Other languages
French (fr)
Other versions
WO2012087004A2 (en
Inventor
Yong Sun Bahn
Kwang Woo Jung
Hyun Ah Kang
Seon Ah Cheon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Industry Academic Cooperation Foundation of Chung Ang University
Industry Academic Cooperation Foundation of Yonsei University
Original Assignee
Industry Academic Cooperation Foundation of Chung Ang University
Industry Academic Cooperation Foundation of Yonsei University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Industry Academic Cooperation Foundation of Chung Ang University, Industry Academic Cooperation Foundation of Yonsei University filed Critical Industry Academic Cooperation Foundation of Chung Ang University
Publication of WO2012087004A2 publication Critical patent/WO2012087004A2/en
Publication of WO2012087004A3 publication Critical patent/WO2012087004A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/26—Endoribonucleases producing 5'-phosphomonoesters (3.1.26)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/37—Assays involving biological materials from specific organisms or of a specific nature from fungi
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • General Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)

Abstract

The present invention relates to the use of the UPR signaling pathway genes IRE1 and HXL1 for treatment of fungal infection and meningitis. In the invention, it was newly found that disruption of Ire1 and Hxl1 (HAC1 and XBP1-Like gene 1) proteins, newly identified in Cryptococcus neoformans, genes encoding the proteins, provides an antifungal effect and a meningitis-treating effect. Based on this finding, a candidate which can show a synergistic effect when being co-administered with an existing antifungal agent or meningitis-treating agent can be screened and a novel pharmaceutical composition having an antifungal effect and a meningitis-treating effect can be provided.
PCT/KR2011/009862 2010-12-23 2011-12-20 Use of upr signaling pathway genes ire1 and hxl1 for treatment of fungal infection and meningitis Ceased WO2012087004A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020100133885A KR101311196B1 (en) 2010-12-23 2010-12-23 Use of IRE1 gene and HXL1 gene in UPR signal pathway for treating mycoses or meningoencephalitis
KR10-2010-0133885 2010-12-23

Publications (2)

Publication Number Publication Date
WO2012087004A2 WO2012087004A2 (en) 2012-06-28
WO2012087004A3 true WO2012087004A3 (en) 2012-10-04

Family

ID=46314614

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2011/009862 Ceased WO2012087004A2 (en) 2010-12-23 2011-12-20 Use of upr signaling pathway genes ire1 and hxl1 for treatment of fungal infection and meningitis

Country Status (2)

Country Link
KR (1) KR101311196B1 (en)
WO (1) WO2012087004A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104164443B (en) * 2014-07-14 2016-11-16 东华大学 A dual-luciferase monitoring plasmid for detecting UPR levels in living yeast cells and its construction and application
RS62386B1 (en) * 2014-10-21 2021-10-29 Hexima Ltd A method of treatment of fungal infections
EP3739058B1 (en) 2015-03-30 2023-07-26 Amtixbio Co., Ltd. Novel gene regulating virulence of cryptococcus neoformans, and use thereof
KR101683002B1 (en) * 2015-07-03 2016-12-07 배재대학교 산학협력단 USE OF sppA GENE AND SppA PROTEIN FOR TREATMENT OF ASPERGILLOSIS
DK3487873T3 (en) * 2016-07-22 2021-05-25 Novozymes As Improved filamentous fungal host
KR20160117380A (en) 2016-07-25 2016-10-10 (주)앰틱스바이오 Novel genes for regulating the virulence of Cryptococcus neoformans and their use
KR20160118162A (en) 2016-07-25 2016-10-11 (주)앰틱스바이오 Novel target genes for anti-fungal agent of Cryptococcus neoformans and their use
KR20170078561A (en) 2017-05-23 2017-07-07 (주)앰틱스바이오 Novel genes for regulating the virulence of Cryptococcus neoformans and their use
CN107308178B (en) * 2017-07-31 2020-11-10 苏州大学附属儿童医院 A drug for parenteral nutrition-related liver disease
US20230296613A1 (en) * 2019-09-18 2023-09-21 Amtixbio Co., Ltd. Use of gene involved in passage through brain-blood barrier and survival inside brain of causative fungi of meningoencephalitis

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BACK, S. H. ET AL.: "ER stress signaling by regulated splicing: IRE1/HAC1/XBP1", METHODS., vol. 35, no. 4, April 2005 (2005-04-01), pages 395 - 416, XP004813160, DOI: doi:10.1016/j.ymeth.2005.03.001 *
CHEON, S. A. ET AL.: "Unique evolution of the UPR pathway with a novel bZIP transcription factor, Hxll, for controlling pathogenicity of Cryptococcus neoformans", PLOS PATHOGENS., vol. 7, no. 8, 11 August 2011 (2011-08-11), pages E1002177 *
FAN, W. ET AL.: "Ecal, a sarcoplasmic/endoplasmic reticulum Ca2+-ATPase, is involved in stress tolerance and virulence in Cryptococcus neoformans", INFECTION AND IMMUNITY., vol. 75, no. 7, 14 May 2007 (2007-05-14), pages 3394 - 3405 *
HU, G. ET AL.: "A putative P-type ATPase, Aptl, is involved in stress tolerance and virulence in Cryptococcus neoformans", EUKARYOTIC CELL., vol. 9, no. 1, 30 November 2009 (2009-11-30), pages 74 - 83 *
MAENG, S. ET AL.: "Comparative transcriptome analysis reveals novel roles of the Ras and cyclic AMP signaling pathways in environmental stress response and antifungal drug sensitivity in Cryptococcus neoformans", EUKARYOTIC CELL., vol. 9, no. 3, 22 January 2010 (2010-01-22), pages 360 - 378 *

Also Published As

Publication number Publication date
KR101311196B1 (en) 2013-09-27
WO2012087004A2 (en) 2012-06-28
KR20120072096A (en) 2012-07-03

Similar Documents

Publication Publication Date Title
WO2012087004A3 (en) Use of upr signaling pathway genes ire1 and hxl1 for treatment of fungal infection and meningitis
EP3986429A4 (en) Platforms, compositions, and methods for therapeutics delivery
HK1210615A1 (en) Cystathionine-y-gamma-lyase (cse) inhibitors
HK1210614A1 (en) Cystathionine-υ-lyase (cse) inhibitors
EP4414369A3 (en) Compounds and methods for the enhanced degradation of targeted proteins
MX2022001292A (en) Stereochemically enriched compositions for delivery of nucleic acids.
WO2012024620A3 (en) Autotaxin inhibitors and uses thereof
MX2009008617A (en) Use of il-23 antagonists for treatment of infection.
MX2016007626A (en) Antimicrobial peptide and uses thereof.
WO2017066622A3 (en) Methods of genomic evaluation in livestock
WO2013169631A3 (en) Wnt protein signalling inhibitors
EP3996686A4 (en) Pegylated synthetic kl4 peptide, compositions and methods thereof
WO2013029011A8 (en) Methods and compositions comprising a c-terminal bax peptide
BR112016023519A2 (en) wnt / ß-catenin signaling inhibitor, pharmaceutical composition and method of treating and / or preventing a pathology defined by vascular malformation
WO2016050835A3 (en) Selective inhibitors of neutrophil elastase for treating neuropathic pain and chronic pain states harbouring a neuropathic component
WO2010103515A3 (en) Compositions and methods for prevention and treatment of neurodegenerative diseases
WO2012090207A3 (en) Par1 and par2 c-tail peptides and peptide mimetics
WO2013192238A3 (en) Compositions and methods for treatment of diabetes
WO2016048007A8 (en) Quorum sensing inhibitor containing d-galactose
MX2015008373A (en) Antimicrobial peptides, compositions comprising the same and uses thereof.
HK1215571A1 (en) Cobicostat dichlohydrate salt
EP2569327A4 (en) EIF4E BINDING PEPTIDES
EP3109640A3 (en) Biomarkers for osteoarthritis
MX2016010431A (en) Compositions for preventing and/or treating pathological conditions associated with alpha-glucosidase.
WO2011103458A3 (en) Compositions and methods for using and identifying antimicrobial agents

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11851763

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11851763

Country of ref document: EP

Kind code of ref document: A2